Physician scientist focused on aging, genitourinary health, and women’s health @UCSFDGIM @UCSFUrology @UCSF_Epibiostat (opinions are my own)
Joined May 2021
- Tweets274
- Following382
- Followers546
- Likes2.7K
Pinned Tweet
Glad to be enrolling older women in our TReatment of Incontinence for Underlying Physical and Mental Health (TRIUMPH) trial—it’s time to study medication effects beyond the bladder: clinicaltrials.ucsf.edu/tria…
Alison Huang, MD, MAS retweeted
Do extension studies to clinical trials increase participants’ motivation to enroll in the original trial?
Or should they be considered cohort studies, not trials in themselves?
📊 Cast your vote in the latest JAMA+ Trials Poll.
🔗 Vote now: ja.ma/4yIkWiu
Alison Huang, MD, MAS retweeted
#ICYMI 🔬@JAMANetwork unveiled @JAMAplusTrials, a resource aimed at highlighting the work of clinical trials while initiating dialogue and education about them. #healthcare
We caught up with JAMA+ Trials' new editor-in-chief to learn more. 🔽
vist.ly/574rw
ALT Banner announcing JAMA Network's new clinical trials resource named JAMA+ Trials. The image features two scientists in a laboratory setting.
This week on JAMA+ Trials with JAMA Health Forum Editor in Chief Sandro Galea, we discuss the gap between what clinical trials typically provide and health policy decisions demand.
Discuss the limitations and new opportunities in trials informing policy:
jamanetwork.com/channels/tri…
💬 Editorial by JAMA+ Trials Editor in Chief Alison Huang, MD, MAS, and JAMA Health Forum Editor in Chief Sandro Galea, MD, DrPH: Policy-oriented clinical trials often struggle to deliver evidence within policy timelines, to measure outcomes meaningful to policymakers, and to inform context-specific implementation.
ja.ma/4ucwyrw
Alison Huang, MD, MAS retweeted
JAMA+ Trials is an online platform celebrating #ClinicalTrials, featuring curated resources, multimedia content, and a searchable collection of trial reports across the JAMA Network.
📝 Read "A Love Letter to Clinical Trials" by EIC Alison Huang, MD, MAS: ja.ma/4wGWEpj
Strategizing on a Saturday for our U2C/TL1 LAUNCH (Learners to LeAders in Urology, Nephrology, non-Cancer Hematology) program at UCSF, Stanford, UC Berkeley, UC Davis:
What do we need to do differently to cultivate the next generation of kidney, urology, hematology scientists?
A Love Letter to Clinical Trials
Sometimes trials deliver the ugly and inconvenient facts that destroy our beautiful hypotheses, which is why we need them.
ja.ma/3QEPcKy
Alison Huang, MD, MAS retweeted
Led by Editor in Chief Alison Huang, MD, MAS, JAMA+ Trials brings together recent clinical trial reports from the 13 JAMA Network journals, multimedia explorations of emerging trends, and educational resources on trial design, conduct, and reporting.
📝 Read the launch editorial: ja.ma/4dOqi51
📬 Sign up for the JAMA+ Trials email newsletter: ja.ma/4mx0WdZ
👉 Follow JAMA+ Trials on X: @JAMAplusTrials
Alison Huang, MD, MAS retweeted
Today, the JAMA Network launches @JAMAplusTrials, a new online platform that highlights the vision, innovation, and resilience of clinical trial research.
Designed for clinicians, investigators, trainees, and others engaged in clinical research worldwide, JAMA+ Trials is an interdisciplinary resource for enhancing insights and promoting dialogue in clinical trial research. 🧵
Alison Huang, MD, MAS retweeted
What does the FDA guidance on Bayesian analysis mean for clinical trials? Leading statisticians weigh in: 🧵
💬 Perspective: FDA recommends transparent quantification of prior influence in bayesian analyses and regular supplementary analyses without informative priors to maintain objectivity.
ja.ma/4lMqgwb
ALT JAMA article \"Reflections on FDA Draft Guidance on Bayesian Methods in Trials\u2014Protecting Scientific Integrity and Evidentiary Standards\" by text@1, text@2, text@3, text@4, published online March 23, 2026.
Is it feasible to teach older women to practice yoga for health indications using remote platforms?
Our participants noted challenges navigating technology, configuring home environments, limited social connection.
But these were offset by facilitators:
doi.org/10.1177/275361302614…
Thanks to NYT's @MaggieAstor for talking about urinary incontinence as a common but underrecognized health issue in women.
Given that one in three women over age 40 have weekly ongoing incontinence, it's a shame that so many women think they are alone:
nytimes.com/2026/01/06/well/…
Glad to discuss this widespread symptom in older adults.
For most, nocturia doesn’t lend itself to a single magic bullet....
nytimes.com/2025/11/04/well/…
Check out today's NYT article on Nocturia, still a hot topic!
Neither panacea nor poison: the swinging pendulum of menopausal hormone therapy
Viewpoint: Menopause care should extend beyond hormone therapy, emphasizing individualized care, clinician training, and evidence-based management. ja.ma/47RGQ8A
Few medications have captured the imagination—and provoked such ire—as menopausal hormone therapy.
For decades, MHT has served as a lightning rod for medical and cultural debate about management of menopause, aging, and women’s health.
doi.org/10.1001/jamainternme…
Impressive results from the PRACTICAL trial led by
@alaynemarkland in @JAMANetworkOpen: a mobile health intervention produced earlier and greater improvement in urinary incontinence than a clinician-based approach involving limited telehealth care:
jamanetwork.com/journals/jam…
Alison Huang, MD, MAS retweeted
Clinicians can enhance patient understanding by using numerical data instead of verbal probabilities, consistent denominators, absolute risk comparisons, and clear context for unfamiliar data types.
ja.ma/42JRNGk
ALT JAMA Insights: How to Communicate Medical Numbers. It outlines recommendations for conveying risk, adjusting numerators, communicating probability changes, using visualizations, and providing context, with examples of problematic and preferred communication styles.
Yes—appreciate their courage. Dissent, thoughtfully expressed, is critical to both scientific inquiry and a functioning society.
Our @UCSFDGIM @UCSF_DOCIT faculty investigator @LisaRotenstein sharing her findings about understaffed physician teams with colleagues and journals at #SGIM25:
Editorial: At #SGIM25, JAMA Internal Medicine featured studies on physician well-being, health equity, and end-of-life care practices. ja.ma/3SsT4fy @pdfriedmann
Glad to discuss the evidence for efficacy and safety of newer non-hormonal treatments for hot flashes with @lindseybever at @washingtonpost, who highlights the need for affordable and well-tolerated options for women with debilitating symptoms:
washingtonpost.com/wellness/…
Estrogen therapy remains the most effective treatment for menopausal vasomotor symptoms, but our @JAMAInternalMed insights article describes evidence-based non-hormonal treatment options for women who are not candidates for or wish to avoid hormones:
doi.org/10.1001/jamainternme…
Hot flashes can be emotionally distressing for midlife women—but will treating hot flashes improve mood?
Clinicians caring for women with both hot flashes and mood symptoms should consider other factors affecting psychological function. @MenopauseJrnl
tinyurl.com/bddu54nf
